FindTrial
Sign In

A Retrospective Study on the Efficacy and Safety of Normothermic Intraperitoneal and Systemic Treatment Combined with Immunotherapy for Peritoneal Metastasis of Gastric Cancer

A Retrospective Study on the Efficacy and Safety of Normothermic Intraperitoneal and Systemic Treatment Combined with Immunotherapy for Peritoneal Metastasis of Gastric Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114566
Enrollment
Unknown
Registered
2025-12-15
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer with peritoneal metastasis

Interventions

Control group:None
Experimental group:None

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Pathologically confirmed as gastric adenocarcinoma; 2.Presence of peritoneal metastasis confirmed by imaging assessment and/or surgical exploration; 3.Received at least two cycles of normothermic intraperitoneal and systemic chemotherapy (NIPS); 4.Having at least three months of complete follow-up data.

Exclusion criteria

Exclusion criteria: 1. Had received intraperitoneal hyperthermic chemotherapy before; 2. Had other primary malignant tumors; 3. Baseline clinical data or key efficacy and safety data were missing and could not be evaluated.

Design outcomes

Primary

MeasureTime frame
Objective response rate;progression-free survival rate;overall survival rate;—

Secondary

MeasureTime frame
The incidence rate of treatment-related adverse reactions;—

Countries

China

Contacts

Public ContactChao Yan

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

yanchaosuper@163.com+86 13681749683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026